Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus FLUORINE F 18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus FLUORINE F 18.
CERETEC vs FLUORINE F-18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Fluorine-18 decays by positron emission, and the emitted positron annihilates with an electron to produce two 511 keV gamma photons. When incorporated into radiopharmaceuticals such as fludeoxyglucose F-18, it accumulates in metabolically active tissues, enabling PET imaging.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
2-10 mCi (74-370 MBq) intravenous bolus, single administration for PET imaging.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Physiological half-life is 109.7 minutes (1.83 hours) for fluorine-18 decay by positron emission, with a physical half-life of 109.7 minutes. The biological half-life is dependent on the radiolabeled compound; for [18F]FDG, the effective half-life is approximately 3-4 hours.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Primarily renal; approximately 95% of administered activity is excreted in urine within 6 hours post-injection. Less than 5% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical